Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2025-12-24 @ 10:09 PM
NCT ID:
NCT06914635
Eligibility Criteria:
Inclusion Criteria:
Line 1: - Age \>18 at time of signing informed consent form
* Signed informed consent form Line 2: - Primery liver tumor
* Age \>18 at time of signing informed consent form
* Signed informed consent form
Exclusion Criteria:
Line 1: - Active or history of neoplastic malignancy
* Active autoimmune disease ongoing treatment with immunosuppressive therapy
* Evidence of positive HIV, HCV, HBV test
* Diabetes
* Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months
* Chronic autoimmune or inflammatory diseases
* Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies
* Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse
* HIV infection
* Failure to sign informed consent form
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
90 Years
Study:
NCT06914635
Study Brief:
Protocol Section:
NCT06914635